TCG Lifesciences Pvt. Ltd., a company controlled by New York-based The Chatterjee Group, has announced that the expansion of its operations in the USA with the establishment of TCG GreenChem Inc., a subsidiary of TCG Lifesciences Pvt. Ltd, to provide CDMO services to global clients.
TCG GreenChem, Inc., offers CMC development services including process research & development and delivery of cGMP APIs. It aims at utilizing its expertise in areas of automated catalysis/reaction screening, reaction optimization, and continuous chemistry.
TCG GreenChem, Inc. is developing processes for selected COVID-19 virus related medicines and other antiviral drugs using new technologies and process schemes under contract with research foundations/hospitals, US Government, and selected biotech companies.
TCG GreenChem, Inc. operates out of a 3,000 SFT lab space in VCU’s Biotechnology Research Park with access to state-of-the-art facilities. It also occupies 54,000 SFT lab/office space in the Princeton South Corporate Center.
Swapan Bhattacharya, Managing Director, TCG Lifesciences Pvt. Ltd. commented, “The priority of our customers today is to find ways to leverage their external partners to fill up a large part of their product development needs. In order to become their preferred partners, we need to provide high quality, efficient and low-cost services which are only possible if we deploy high-end talents and skills that can drive innovation. TCG GreenChem has an exceptional management team, technological expertise and know-how, which is critical for the development of architecturally complex intermediates and APIs by utilizing state-of-the-art synthetic organic chemistry.”
Dr. Chris H. Senanayake, CEO and CSO, TCG GreenChem, Inc. added, “We are excited to be a part of TCG Lifesciences Pvt. Ltd., as they are highly valued by their pharmaceutical partners and have a reputation of embracing innovation and high-end technology which are the cornerstones of the TCG GreenChem’s strategy. Our mission is to create a “technology innovator” CDMO, to partner with the pharmaceutical, biotechnology, and generic industries in delivering integrated, accelerated, and economical services utilizing green sustainable technologies with a global footprint. Leveraging our knowledge of drug development and commercialization, we want to be the Drug Development Engine “Accelerating Molecules to Medicines” by advancing preclinical candidates into phase I and beyond, for our clients and partners.”
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.